MA52624A - Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r - Google Patents
Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4rInfo
- Publication number
- MA52624A MA52624A MA052624A MA52624A MA52624A MA 52624 A MA52624 A MA 52624A MA 052624 A MA052624 A MA 052624A MA 52624 A MA52624 A MA 52624A MA 52624 A MA52624 A MA 52624A
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitor
- administration
- treatment
- methods
- atopic dermatitis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862670824P | 2018-05-13 | 2018-05-13 | |
US201962840493P | 2019-04-30 | 2019-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA52624A true MA52624A (fr) | 2021-03-24 |
Family
ID=66641513
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA052624A MA52624A (fr) | 2018-05-13 | 2019-05-10 | Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r |
Country Status (12)
Country | Link |
---|---|
US (2) | US11292847B2 (fr) |
EP (1) | EP3793597A1 (fr) |
JP (2) | JP2021523188A (fr) |
KR (1) | KR20210010518A (fr) |
CN (1) | CN112153982A (fr) |
AU (1) | AU2019270940A1 (fr) |
BR (1) | BR112020020387A2 (fr) |
CA (1) | CA3099066A1 (fr) |
MA (1) | MA52624A (fr) |
MX (1) | MX2020012064A (fr) |
SG (1) | SG11202009371WA (fr) |
WO (1) | WO2019222055A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI755763B (zh) | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法 |
KR20220070544A (ko) | 2014-02-28 | 2022-05-31 | 리제너론 파아마슈티컬스, 인크. | Il-4r 길항제의 투여에 의한 피부 감염의 치료 방법 |
CN107474134B (zh) | 2016-06-08 | 2021-07-27 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
AU2017321682A1 (en) | 2016-09-01 | 2019-04-11 | Regeneron Pharmaceuticals, Inc. | Methods for preventing or treating allergy by administering an IL-4R antagonist |
WO2019028367A1 (fr) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | Méthodes de traitement de l'oesophagite à éosinophiles active |
PT3515465T (pt) | 2017-08-18 | 2024-03-04 | Regeneron Pharma | Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r |
SG11202109002XA (en) | 2019-03-21 | 2021-09-29 | Regeneron Pharma | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
MX2022001247A (es) * | 2019-08-05 | 2022-04-25 | Regeneron Pharma | Metodos para tratar dermatitis atopica mediante la administracion de un antagonista il-4r. |
AU2020325021A1 (en) | 2019-08-05 | 2022-01-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8808015D0 (en) | 1988-04-06 | 1988-05-05 | Ritter M A | Chemical compounds |
AU643427B2 (en) | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
AU665763B2 (en) | 1991-05-03 | 1996-01-18 | Seragen, Inc. | Interleukin receptor targeted molecules for treatment of inflammatory arthritis |
JP3315427B2 (ja) | 1992-03-05 | 2002-08-19 | 大日本除蟲菊株式会社 | 皮膚炎治療剤 |
US5714146A (en) | 1992-08-26 | 1998-02-03 | Board Of Regents Of The University Of Washington | IL-4 bone therapy |
EP0604693A1 (fr) | 1992-12-29 | 1994-07-06 | Schering-Plough | Anticorps monoclonaux contre le récepteur de l'interleukine-4 humain et hydridomes les produisant |
RU2162711C2 (ru) | 1993-09-07 | 2001-02-10 | Смитклайн Бичам Корпорейшн | Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4 |
ATE326239T1 (de) | 1998-09-18 | 2006-06-15 | Dynavax Tech Corp | Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren |
ES2549767T3 (es) | 2000-05-26 | 2015-11-02 | Immunex Corporation | Uso de anticuerpos de interleuquina-4 y composiciones de los mismos |
US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
ATE372764T1 (de) | 2000-07-26 | 2007-09-15 | Hououdou Co Ltd | Antipruritische zusammensetzungen und die wundheilung fördernde zusammensetzungen |
US20030103938A1 (en) | 2001-05-09 | 2003-06-05 | Alk-Abello A/S | Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio |
US20050031609A1 (en) | 2001-05-11 | 2005-02-10 | Thomas Hultsch | Compositions for use in treating ige-associated disorders |
WO2002093998A2 (fr) | 2001-05-23 | 2002-11-28 | Duotol Ab | Suppression de reactions allergiques par administration intradermique d'allergenes conjugues avec des sous unites de toxine ou des fragments de celle-ci |
DK1461300T3 (da) | 2001-11-30 | 2011-10-24 | Biogen Idec Inc | Antistoffer mod kemotaktiske monocytproteiner |
PT1527100E (pt) | 2002-03-29 | 2009-08-25 | Schering Corp | Anticorpos monoclonais humanos para interleucina-5 e métodos e composições compreendendo os mesmos |
DK2407485T3 (en) | 2003-02-01 | 2016-03-21 | Tanox Inc | Anti-human IgE antibodies with high affinity |
US7923209B2 (en) | 2003-03-14 | 2011-04-12 | Anergis, S.A. | Allergen peptide fragments and use thereof |
BRPI0416603A (pt) | 2003-11-07 | 2007-01-30 | Immunex Corp | anticorpo que se liga ao receptor interleucina-4 (il-4) humano |
US7884054B2 (en) | 2003-12-22 | 2011-02-08 | Amgen Inc. | Methods for identifying functional antibodies |
AU2005219837A1 (en) | 2004-02-27 | 2005-09-15 | Regeneron Pharmaceuticals, Inc. | IL-4/IL-13 sepecific polypetides and therapeutic uses thereof |
US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
JP5234445B2 (ja) | 2004-10-05 | 2013-07-10 | 源一郎 杣 | 薬剤 |
US8030003B2 (en) | 2004-12-07 | 2011-10-04 | Children's Hospital Medical Center | Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3 |
TW200902555A (en) | 2005-01-03 | 2009-01-16 | Hoffmann La Roche | Antibodies against IL-13 receptor alpha 1 and uses thereof |
US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
JP4221018B2 (ja) | 2006-08-31 | 2009-02-12 | トヨタ自動車株式会社 | 頭部保護エアバッグ装置 |
US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
PL2069403T3 (pl) | 2006-10-02 | 2015-08-31 | Regeneron Pharma | Przeciwciała ludzkie o wysokim powinowactwie wobec receptora ludzkiej IL-4 |
CA2681341A1 (fr) | 2007-03-22 | 2008-09-25 | Genentech, Inc. | Anticorps anti-ige apoptopiques |
EP2022507A1 (fr) | 2007-08-07 | 2009-02-11 | Universität Hamburg | Compositions d'anticorps spécifiques pour les épitopes des lgE, lgG4 et lgA en tant qu'outils pour la création de molécules hypoallergéniques pour l'immunothérapie spécifique |
US8637239B2 (en) | 2007-11-05 | 2014-01-28 | The Board Of Trustees Of The University Of Illinois | Minimally-invasive measurement of esophageal inflammation |
US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
DE202008006598U1 (de) | 2008-04-11 | 2008-10-02 | Alk-Abelló A/S | Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung |
US20090264392A1 (en) | 2008-04-21 | 2009-10-22 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
US20120004205A1 (en) | 2008-12-01 | 2012-01-05 | Cincinnati Children's Hospital Medical Center | Il-13 induced gene signature for eosinophilic esophagitis |
WO2010120524A2 (fr) | 2009-03-31 | 2010-10-21 | Altair Therapeutics, Inc. | Procédés de modulation d'une réponse immunitaire à une infection virale |
US8497528B2 (en) | 2010-05-06 | 2013-07-30 | Taiwan Semiconductor Manufacturing Company, Ltd. | Method for fabricating a strained structure |
CA2773234C (fr) | 2009-09-07 | 2017-11-28 | Dbv Technologies | Methode de traitement d'oesophagite eosinophile |
US8993347B2 (en) | 2009-12-17 | 2015-03-31 | Cornell University | Methods for detecting antibodies in mucosal samples and device for sampling mucosal material |
ES2894936T3 (es) | 2010-06-24 | 2022-02-16 | Viropharma Biologics Llc | Métodos de tratamiento para la inflamación del esófago |
EP3733711A1 (fr) | 2010-10-06 | 2020-11-04 | Regeneron Pharmaceuticals, Inc. | Formulations stabilisées contenant des anticorps anti-récepteur de l'interleukine-4 (il-4r) |
RU2453303C1 (ru) | 2010-12-23 | 2012-06-20 | Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") | Фармацевтическая композиция для лечения атопического дерматита |
EP2661631A4 (fr) | 2011-01-06 | 2014-05-21 | Childrens Hosp Medical Center | Profils d'expression de cytokine sophagienne dans l' sophagite à éosinophiles |
US20130052190A1 (en) | 2011-02-22 | 2013-02-28 | Oxagen Limited | CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions |
US9928344B2 (en) | 2011-06-21 | 2018-03-27 | Children's Hospital Medical Center | Diagnostic methods of eosinophilic esophagitis |
US20140303067A1 (en) | 2011-10-06 | 2014-10-09 | N.V. Nutricia | Treatment of eosinophilic esophagitis |
MX2014007239A (es) | 2011-12-16 | 2014-08-08 | Atopix Therapeutics Ltd | Combinacion de un antagonista crth2 y un inhibidor de bomba de proton para el tratamiento de esofagitis eosinofilica. |
BR112014018471A2 (pt) | 2012-01-31 | 2017-07-04 | Genentech Inc | anticorpos anti-ige m1' e métodos para o seu uso |
WO2013155010A1 (fr) | 2012-04-09 | 2013-10-17 | Children's Hospital Medical Center | Biomarqueurs non invasifs pour l'œsophagite éosinophile |
AU2013305945B2 (en) | 2012-08-21 | 2018-07-26 | Regeneron Pharmaceuticals Inc. | Methods for treating or preventing asthma by administering an IL-4R antagonist |
SG10201701798TA (en) * | 2012-09-07 | 2017-04-27 | Regeneron Pharma | Methods for treating atopic dermatitis by administering an il-4r antagonist |
US10132809B2 (en) | 2012-10-10 | 2018-11-20 | Rhote Island Hospital | Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis |
ES2829499T3 (es) | 2013-02-05 | 2021-06-01 | Engmab Sarl | Método para la selección de anticuerpos contra BCMA |
TWI755763B (zh) | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
TWI709411B (zh) | 2013-06-21 | 2020-11-11 | 法商賽諾菲生物技術公司 | Il-4r拮抗劑用於製備治療鼻息肉症的醫藥品之用途 |
TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法 |
WO2015127229A1 (fr) | 2014-02-21 | 2015-08-27 | Sanofi | Méthodes de traitement ou de prévention de l'asthme par administration d'un antagoniste d'il-4 r |
KR20220070544A (ko) | 2014-02-28 | 2022-05-31 | 리제너론 파아마슈티컬스, 인크. | Il-4r 길항제의 투여에 의한 피부 감염의 치료 방법 |
EP3218412A1 (fr) * | 2014-11-14 | 2017-09-20 | Sanofi Biotechnology | Méthodes de traitement de la sinusite chronique avec polypose nasale par administration d'un antagoniste d'il-4r |
CN109069625A (zh) | 2016-02-19 | 2018-12-21 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂来增强疫苗功效的方法 |
CN107474134B (zh) | 2016-06-08 | 2021-07-27 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
TWI728172B (zh) | 2016-08-18 | 2021-05-21 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
AU2017321682A1 (en) | 2016-09-01 | 2019-04-11 | Regeneron Pharmaceuticals, Inc. | Methods for preventing or treating allergy by administering an IL-4R antagonist |
IL268349B1 (en) | 2017-02-17 | 2024-04-01 | Hutchinson Fred Cancer Res | Combination therapies for the treatment of BCMA-associated cancer and autoimmune disorders |
US20200179511A1 (en) | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
WO2019028367A1 (fr) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | Méthodes de traitement de l'oesophagite à éosinophiles active |
PT3515465T (pt) | 2017-08-18 | 2024-03-04 | Regeneron Pharma | Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r |
US11034768B2 (en) | 2017-10-30 | 2021-06-15 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
SG11202109002XA (en) | 2019-03-21 | 2021-09-29 | Regeneron Pharma | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
MX2022001247A (es) | 2019-08-05 | 2022-04-25 | Regeneron Pharma | Metodos para tratar dermatitis atopica mediante la administracion de un antagonista il-4r. |
AU2020325021A1 (en) | 2019-08-05 | 2022-01-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist |
EP4153300A1 (fr) | 2020-05-22 | 2023-03-29 | Regeneron Pharmaceuticals, Inc. | Méthodes de traitement de l'oesophagite à éosinophiles par administration d'un inhibiteur d'il-4r |
-
2019
- 2019-05-10 CA CA3099066A patent/CA3099066A1/fr active Pending
- 2019-05-10 JP JP2020563960A patent/JP2021523188A/ja active Pending
- 2019-05-10 MA MA052624A patent/MA52624A/fr unknown
- 2019-05-10 AU AU2019270940A patent/AU2019270940A1/en active Pending
- 2019-05-10 WO PCT/US2019/031801 patent/WO2019222055A1/fr unknown
- 2019-05-10 SG SG11202009371WA patent/SG11202009371WA/en unknown
- 2019-05-10 US US16/409,164 patent/US11292847B2/en active Active
- 2019-05-10 EP EP19726273.6A patent/EP3793597A1/fr active Pending
- 2019-05-10 CN CN201980032103.7A patent/CN112153982A/zh active Pending
- 2019-05-10 BR BR112020020387-4A patent/BR112020020387A2/pt unknown
- 2019-05-10 KR KR1020207035859A patent/KR20210010518A/ko unknown
- 2019-05-10 MX MX2020012064A patent/MX2020012064A/es unknown
-
2022
- 2022-03-04 US US17/687,051 patent/US20220298250A1/en active Pending
-
2024
- 2024-01-04 JP JP2024000024A patent/JP2024038234A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220298250A1 (en) | 2022-09-22 |
BR112020020387A2 (pt) | 2021-01-19 |
EP3793597A1 (fr) | 2021-03-24 |
KR20210010518A (ko) | 2021-01-27 |
NZ769607A (en) | 2023-11-24 |
WO2019222055A1 (fr) | 2019-11-21 |
MX2020012064A (es) | 2021-04-13 |
US20190345253A1 (en) | 2019-11-14 |
CN112153982A (zh) | 2020-12-29 |
CA3099066A1 (fr) | 2019-11-21 |
AU2019270940A1 (en) | 2020-11-26 |
JP2021523188A (ja) | 2021-09-02 |
SG11202009371WA (en) | 2020-10-29 |
JP2024038234A (ja) | 2024-03-19 |
US11292847B2 (en) | 2022-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA52624A (fr) | Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r | |
MA46098A (fr) | Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r | |
MA46102A (fr) | Composés de tétracycline et méthodes de traitement | |
MA52371A (fr) | Méthodes de traitement d'infections dues aux coronaviridae | |
MA43135A (fr) | Compositions et méthodes pour le du traitement du cancer | |
EA201890307A1 (ru) | Индазольные и азаиндазольные соединения как ингибиторы irak-4 | |
MA46269A (fr) | Méthodes de traitement d'une dermatite atopique sévère par administration d'un inhibiteur des il-4r | |
MA44083A (fr) | Composés de biarylmonobactame pour le traitement d'infections bactériennes | |
FR3046933B1 (fr) | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires | |
EA201691516A1 (ru) | Дигидропирролопиридиновые ингибиторы ror-гамма | |
PE20190338A1 (es) | Metodos de tratamiento de trastornos del desarrollo con gaboxadol | |
EA201890185A1 (ru) | Способы лечения опосредованных гепсидином нарушений | |
EA201791095A1 (ru) | Способ лечения рака | |
FR3014694B1 (fr) | Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl | |
MA43811A (fr) | Composés d'arylmonobactame bicycliques et leurs méthodes d'utilisation pour le traitement des infections bactériennes | |
EA201792496A1 (ru) | Способы лечения воспаления или нейропатической боли | |
MA44234A (fr) | Procédés de traitement ou de prévention de l'athérosclérose par administration d'un inhibiteur d'angptl3 | |
MA47504A (fr) | Composés et méthodes de traitement de l'angiocholite biliaire primitive | |
MA47362A (fr) | Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif | |
MA51056A (fr) | Compositions et méthodes pour le traitement d'affections métaboliques | |
MA48730A (fr) | Compositions et méthodes de traitement de synucléinopathies | |
EA202091020A1 (ru) | Замещенные имидазопиридинамиды и их применение | |
EA201891468A1 (ru) | Композиции и способы для снижения экспрессии tau | |
MA55807A (fr) | Méthodes de traitement ou de prévention de l'asthme par administration d'un antagoniste d'il-33 | |
MA43800A (fr) | Octréotide par voie orale pour le traitement de maladies |